Jazz Pharmaceuticals, Inc. (JAZZ) News
Latest headlines that mention JAZZ, newest first · each headline opens the original publisher
- Last price
- $210.23
- Day change
- -1.95%
- Next earnings
- 2026-11-04
JAZZ headlines
latest coverageJim Cramer backed the tumbling pharma stock, even though JAZZ shares have fallen during the past month.
Actio could make Jazz's growing epilepsy franchise even stronger.
Jazz Pharmaceuticals (JAZZ) just made a bet on a disease that many investors have never heard of. On August 10, the drugmaker agreed to buy privately held Actio Biosciences. The prize is an experimental medicine aimed at a childhood epilepsy so rare, and so severe, that no…
Revenue hit $1.2 billion with oncology sales surging and Xywav demand accelerating.
JAZZ news alerts
Get an alert by email or push when a new headline mentions JAZZ.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.